Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Fahri Akgül"'
Autor:
İvo Gökmen, Nazan Demir, Pınar Peker, Erkan Özcan, Fahri Akgül, İsmail Bayrakçı, Didem Divriklioğlu, Bülent Erdoğan, Sernaz Topaloğlu, Muhammet Bekir Hacıoğlu
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveThe aim of our study was to assess the impact of the combination of HALP score with TTCR score on OS and PFS in PC patients who developed castration resistance.Patients and methodsThe study enrolled 152 patients with metastatic disease who h
Externí odkaz:
https://doaj.org/article/52359d4eed0840de98ac9f4e24b298fe
Autor:
İvo Gökmen, Ebru Taştekin, Nazan Demir, Erkan Özcan, Fahri Akgül, Muhammed Bekir Hacıoğlu, Bülent Erdoğan, Sernaz Topaloğlu, İrfan Çiçin
Publikováno v:
Current Issues in Molecular Biology, Vol 45, Iss 10, Pp 7803-7812 (2023)
The aim of our study was to evaluate the incidence of KRAS/NRAS and BRAF mutations, analyze molecular patterns, and investigate associations with clinical parameters of these mutations in CRC KRAS/NRAS and BRAF mutations analyzed by next-generation s
Externí odkaz:
https://doaj.org/article/136914033b38496a91f9524dc2a50894
Autor:
Sabin Göktaş Aydın, Burçin Çakan Demirel, Ahmet Bilici, Cansu Yilmaz, Atakan Topçu, Musa Barış Aykan, Seda Kahraman, Muhammed Mustafa Atcı, Ilgın Akbıyık, Fahri Akgül, Ömer Fatih Ölmez, Ahmet Aydın
Introduction: There is a lack of evidence of the outcomes in elderly patients advanced stage biliary tract cancer due to the patients aged over 65 years are less than 25% in many prospective trials. We designed a retrospective multicenter study to ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a19e07c664da1df182010721d559aa60
https://hdl.handle.net/20.500.12511/11031
https://hdl.handle.net/20.500.12511/11031
Publikováno v:
Immunotherapy. 14(6)
Introduction: The case of a patient who developed recurrent delayed immune-related pneumonitis (checkpoint inhibitor pneumonitis [CIP]) after immune checkpoint inhibitor (ICI) therapy for advanced osteosarcoma treatment is presented. Case summary: A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24cb72c19bb951db5ccb6fe65e42aba
https://pubmed.ncbi.nlm.nih.gov/35152716
https://pubmed.ncbi.nlm.nih.gov/35152716
Autor:
Sabin Goktas Aydin, Engin Eren Kavak, Atakan Topcu, Ayberk Bayramgil, Fahri Akgul, Seda Kahraman, Musa Baris Aykan, Yunus Emre Altıntas, Kaan Helvaci, Yuksel Urun, Ahmet Bilici, Mesut Seker, Mehmet Ali Nahit Sendur, Omer Fatih Olmez, Ozgur Acikgoz, Irfan Cicin
Publikováno v:
Biomolecules & Biomedicine, Vol 23, Iss 6 (2023)
Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess t
Externí odkaz:
https://doaj.org/article/307cb5703f46446fb0e16815e2f38f8b